{"id":"abbv-951","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABBV-951 activates the glucagon-like peptide-1 (GLP-1) receptor, which enhances insulin secretion in response to glucose, slows gastric emptying, and promotes satiety. The long-acting formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists, improving patient convenience and adherence.","oneSentence":"ABBV-951 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:37.101Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Obesity or weight management"}]},"trialDetails":[{"nctId":"NCT06639620","phase":"","title":"Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2024-11-12","conditions":"Advanced Parkinson Disease","enrollment":250},{"nctId":"NCT06107426","phase":"","title":"Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-01-24","conditions":"Parkinson's Disease (PD)","enrollment":450},{"nctId":"NCT04750226","phase":"PHASE3","title":"Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2021-02-18","conditions":"Parkinson's Disease (PD)","enrollment":118},{"nctId":"NCT04379050","phase":"PHASE3","title":"Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-06-08","conditions":"Parkinson's Disease (PD)","enrollment":130},{"nctId":"NCT05916157","phase":"","title":"An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-11-30","conditions":"Parkinson's Disease (PD)","enrollment":250},{"nctId":"NCT03374917","phase":"PHASE1","title":"A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-04-18","conditions":"Parkinson's Disease (PD)","enrollment":20},{"nctId":"NCT03033498","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-17","conditions":"Parkinson's Disease (PD)","enrollment":29},{"nctId":"NCT03781167","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-04-29","conditions":"Parkinson's Disease (PD)","enrollment":244},{"nctId":"NCT05094050","phase":"PHASE1","title":"Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-01-18","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT04380142","phase":"PHASE3","title":"Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-10-19","conditions":"Parkinson's Disease (PD)","enrollment":174}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"PAPILLARY THYROID CANCER"},{"count":1,"reaction":"PROSTATE CANCER"},{"count":1,"reaction":"PSYCHOTIC DISORDER"}],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Foslevodopa/Foscarbidopa","Foscarbidopa","Foslevodopa","Foslevodopa/foscarbidopa"],"phase":"phase_3","status":"active","brandName":"ABBV-951","genericName":"ABBV-951","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABBV-951 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. Used for Type 2 diabetes mellitus, Obesity or weight management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}